Abstract: Present disclosure provides a method including isolating DNA from a source, thereby providing a composition including the isolated DNA. The isolated DNA has at least first and second target regions, where the length of the second target region is greater than the length of the first target region. The method further includes quantifying a total mass of the isolated DNA, quantifying a first quantification cycle (Cq) of the first target region and a second Cq of the second target region, and calculating a Q-ratio for the isolated DNA by dividing the second Cq by the first Cq. The method further includes determining a value for a quality-mass constant (kQm), estimating a required input mass by dividing kQm by the Q-ratio, and preparing the isolated DNA for sequencing if the total mass of the isolated DNA in the composition is equal or greater than the required input mass.

Abstract: The invention is a method of predicting recurrence of colorectal cancer in a patient following surgery, the method comprising analysis of circulating tumor DNA from a patient's sample.

Abstract: The present invention provides method essentially comprising the steps of (i) providing a DNA sample, (ii) providing at least a first pair of amplification primers which is capable of generating a first amplicon from a LINE sequence that has a size of less than 80 bp, (iii) providing at least a second pair of amplification primers which is capable of generating a second amplicon from a LINE sequence that has a size of more than 160 bp, (iv) performing a qPCR and determining cq values for each of the generated amplicons, and (v) determining the relative concentrations of said amplicons.

Abstract: The present invention provides method essentially comprising the steps of (i) providing a DNA sample, (ii) providing at least a first pair of amplification primers which is capable of generating a first amplicon from a LINE sequence that has a size of less than 80 bp, (iii) providing at least a second pair of amplification primers which is capable of generating a second amplicon from a LINE sequence that has a size of more than 160 bp, (iv) performing a qPCR and determining cq values for each of the generated amplicons, and (v) determining the relative concentrations of said amplicons.

Abstract: Present disclosure provides a method including isolating DNA from a source, thereby providing a composition including the isolated DNA. The isolated DNA has at least first and second target regions, where the length of the second target region is greater than the length of the first target region. The method further includes quantifying a total mass of the isolated DNA, quantifying a first quantification cycle (Cq) of the first target region and a second Cq of the second target region, and calculating a Q-ratio for the isolated DNA by dividing the second Cq by the first Cq. The method further includes determining a value for a quality-mass constant (kQm), estimating a required input mass by dividing kQm by the Q-ratio, and preparing the isolated DNA for sequencing if the total mass of the isolated DNA in the composition is equal or greater than the required input mass.

Abstract: The invention is a method of predicting recurrence of colorectal cancer in a patient following surgery, the method comprising analysis of circulating tumor DNA from a patient's sample.

Abstract: The invention pertains to a method for early detection and screening of colorectal cancer in human subjects based on RNA isolated from blood obtained from said subject. According to the invention, the abundance of at least 3, 5, 8, 30, 60, 102, 202, 55, 1002 or 1002 RNAs listed in tables 1 to 13 is measured. Using the invention, an accurate and noninvasive screening and diagnosis tool for colorectal cancer is provided with a sensitivity of at least 80% and a specificity of 85% that has high clinical utility and the potential for broad adoption.

Abstract: The invention pertains to a method for early detection and screening of colorectal cancer in human subjects based on RNA isolated from blood obtained from said subject. According to the invention, the expression of at least 3, 5, 8, 30, 60, 102, 202, 55, 1002 or 1002 RNAs listed in Tables 1-15 are measured. Using the invention, an accurate and noninvasive screening and diagnosis tool for colorectal cancer is provided with a sensitivity of at least 80% and a specificity of 85% that has high clinical utility and the potential for broad adoption.

Abstract: The invention relates to the use of gene expression profiles for predicting the probability of recurrence or metastases to develop in remote organs of patients from which a primary colon carcinoma has been removed.

Abstract: Human nucleic acid sequences—mRNA, cDNA, genomic sequences—from tissue of prostate tumors, which code for gene products or parts thereof and their use, are described. In addition, the polypeptides that can be obtained by way of the sequences and their use are described.

Abstract: Human nucleic acid sequences—mRNA, cDNA, genomic sequences—from normal pancreatic tissue, which code for gene products or portions thereof, and their use, are described. In addition, the polypeptides that can be obtained by way of the sequences and their use are described.

Abstract: Human nucleic acid sequences—mRNA, cDNA, genomic sequences—from breast tumor tissue, which code for gene products or parts thereof, and their use, are described. In addition, the polypeptides that can be obtained by way of the sequences and their use are described.

Abstract: Human nucleic acid sequences—mRNA, cDNA, genomic sequences—from endometrial tumor tissue, which code for gene products or portions thereof, and their use, are described. In addition, the polypeptides that can be obtained by way of the sequences and their use are described.

Abstract: The invention relates to a process for detecting differential gene expressions and new nucleic acid sequences that can be obtained by this process.

Abstract: The invention relates to human nucleic acid sequences—mRNA, cDNA, genome sequences—of ovarian tumour tissue, which code for gene products or parts of these products, and to their use. The invention also relates to the polypeptides obtained by way of these sequences and to the use of same.

Abstract: DNA sequences for human matrix metalloproteases are disclosed, as well as homologous DNA sequences homologous and derived therefrom. Also disclosed are the proteins and protein variants coded by these DNA sequences, there expression, preparation and use. The invention has applications in the fields of biomolecular, medical and pharmaceutical research, for medical diagnosis and therapy, and in the pharmaceutical and biotechnological industry.

Abstract: The invention relates to matrix metalloproteases and variants thereof and DNA sequences that encode these matrix metalloproteases. The invention further relates to obtaining the matrix metalloproteases from natural sources or by recombinant methods by expression of the DNA sequences. These matrix metalloproteases can also complexed with a ligand. The matrix metalloproteases are enzymes that hydrolyze one or more proteins of the extracellular matrix and are thought to contribute to local degradation of the extracellular matrix in tumor cell invasion and metastasis, rheumatoid arthritis, aneurysm formation, smooth muscle proliferation and migration processes in atherosclerotic disease.